# Seeds/Tissue Culture/Bio Technology — company-by-company sector analysis

> Seeds/Tissue Culture/Bio Technology: Rossari Biotech Ltd owns the largest revenue base AND the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-07-29. Not investment advice.

## Bottom line

Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 27.1% over 52 weeks and 4.8% over 13 weeks. 1 of 3 covered companies beat NIFTY on Mansfield relative strength, while 2 of 3 beat the sector itself. Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026.

### Is the Seeds/Tissue Culture/Bio Technology sector outperforming NIFTY 500?

Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 27.1% over 52 weeks and 4.8% over 13 weeks. 1 of 3 covered companies beat NIFTY on Mansfield relative strength, while 2 of 3 beat the sector itself.

### Which Seeds/Tissue Culture/Bio Technology company is largest by revenue?

Rossari Biotech Ltd leads with revenue of ₹2,550 crore, based on 3 of 3 comparable companies through Jun 2026.

### Which Seeds/Tissue Culture/Bio Technology company is growing fastest?

Rossari Biotech Ltd has the fastest current revenue growth at 19.4%, across 3 of 3 comparable companies.

### Which Seeds/Tissue Culture/Bio Technology company has the strongest 4-Factor Sector Score?

Advanced Enzyme Technologies Ltd ranks first at 73.1/100 with 76% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Seeds/Tissue Culture/Bio Technology company has the least gross debt?

Advanced Enzyme Technologies Ltd has the lowest comparable gross debt at ₹32 crore. Rossari Biotech Ltd has the highest at ₹436 crore.

### Which Seeds/Tissue Culture/Bio Technology company has the lowest comparable PEG?

Rossari Biotech Ltd has the lowest comparable Guarded PEG at 1.7, among 1 of 3 companies that pass the metric’s comparability rules.

### How much history does this Seeds/Tissue Culture/Bio Technology comparison include?

The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

## Sector relative strength

Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 27.1% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 4.8%. 1 of 3 covered companies currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Advanced Enzyme Technologies Ltd is the strongest against the sector itself at +13.5%.

13-week sector return versus NIFTY 500: -4.8%
52-week sector return versus NIFTY 500: -27%
Stocks leading NIFTY: 1/3
Stocks leading sector: 2/3

Central tension: The central tension: current leadership is concentrated, so durability matters more than rank.

Companies: 3
Combined market value: ₹7.2K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Advanced Enzyme Technologies Ltd (ADVENZYMES): 73/100 — Favorable setup; evidence 76%
   - Growth & earnings 27.8/35 | Capital efficiency 17.5/25 | Valuation 12.1/20 | Relative strength 15.7/20
   - Exact sum: 27.8 + 17.5 + 12.1 + 15.7 = 73.1
   - Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2. Rossari Biotech Ltd (ROSSARI): 54/100 — Mixed-positive evidence; evidence 97%
   - Growth & earnings 20.4/35 | Capital efficiency 12.8/25 | Valuation 12.7/20 | Relative strength 7.9/20
   - Exact sum: 20.4 + 12.8 + 12.7 + 7.9 = 53.8
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 34/100 — Adverse evidence; evidence 74%
   - Growth & earnings 5.7/35 | Capital efficiency 12.7/25 | Valuation 12.2/20 | Relative strength 3.0/20
   - Exact sum: 5.7 + 12.7 + 12.2 + 3 = 33.6
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

## Revenue Scale & Growth Durability

What the numbers say: Rossari Biotech Ltd is the scale leader at ₹2,550 crore, 241.8% ahead of Advanced Enzyme Technologies Ltd. Rossari Biotech Ltd's growth is 19.4% from a ₹2,550 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Rossari Biotech Ltd is the scale benchmark; Rossari Biotech Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Rossari Biotech Ltd's growth falls below Rossari Biotech Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Rossari Biotech Ltd · ₹2,550 crore | 241.8% versus #2 · Advanced Enzyme Technologies Ltd | 8/8 recent comparable periods | 3/3 companies · 48 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Rossari Biotech Ltd (ROSSARI): ₹2.6K Cr
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): ₹746 Cr
3. Bombay Super Hybrid Seeds Ltd (BSHSL): ₹344 Cr

### Revenue growth — fastest growers
1. Rossari Biotech Ltd (ROSSARI): 19%
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): 17%
3. Bombay Super Hybrid Seeds Ltd (BSHSL): -4.1%

### 20-quarter Revenue history
- ADVENZYMES: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹142 Cr | Mar 2023 ₹139 Cr | Jun 2023 ₹147 Cr | Sep 2023 ₹158 Cr | Dec 2023 ₹161 Cr | Mar 2024 ₹158 Cr | Jun 2024 ₹155 Cr | Sep 2024 ₹146 Cr | Dec 2024 ₹169 Cr | Mar 2025 ₹167 Cr | Jun 2025 ₹186 Cr | Sep 2025 ₹185 Cr | Dec 2025 ₹172 Cr | Mar 2026 ₹203 Cr | Jun 2026 —
- ROSSARI: Sep 2021 ₹385 Cr | Dec 2021 ₹428 Cr | Mar 2022 ₹439 Cr | Jun 2022 ₹435 Cr | Sep 2022 ₹425 Cr | Dec 2022 ₹389 Cr | Mar 2023 ₹406 Cr | Jun 2023 ₹411 Cr | Sep 2023 ₹483 Cr | Dec 2023 ₹464 Cr | Mar 2024 ₹473 Cr | Jun 2024 ₹490 Cr | Sep 2024 ₹498 Cr | Dec 2024 ₹513 Cr | Mar 2025 ₹580 Cr | Jun 2025 ₹544 Cr | Sep 2025 ₹586 Cr | Dec 2025 ₹582 Cr | Mar 2026 ₹685 Cr | Jun 2026 ₹697 Cr
- BSHSL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹69 Cr | Mar 2023 ₹36 Cr | Jun 2023 ₹117 Cr | Sep 2023 ₹34 Cr | Dec 2023 ₹76 Cr | Mar 2024 ₹30 Cr | Jun 2024 ₹157 Cr | Sep 2024 ₹28 Cr | Dec 2024 ₹128 Cr | Mar 2025 ₹46 Cr | Jun 2025 ₹153 Cr | Sep 2025 ₹27 Cr | Dec 2025 ₹98 Cr | Mar 2026 ₹66 Cr | Jun 2026 —

### 20-quarter Revenue growth history
- ADVENZYMES: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 13% | Mar 2024 14% | Jun 2024 5.4% | Sep 2024 -7.6% | Dec 2024 5.0% | Mar 2025 5.7% | Jun 2025 20% | Sep 2025 27% | Dec 2025 1.8% | Mar 2026 22% | Jun 2026 —
- ROSSARI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 10% | Dec 2022 -9.1% | Mar 2023 -7.5% | Jun 2023 -5.5% | Sep 2023 14% | Dec 2023 19% | Mar 2024 17% | Jun 2024 19% | Sep 2024 3.1% | Dec 2024 11% | Mar 2025 23% | Jun 2025 11% | Sep 2025 18% | Dec 2025 13% | Mar 2026 18% | Jun 2026 28%
- BSHSL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 11% | Mar 2024 -16% | Jun 2024 34% | Sep 2024 -16% | Dec 2024 67% | Mar 2025 52% | Jun 2025 -2.4% | Sep 2025 -4.8% | Dec 2025 -23% | Mar 2026 45% | Jun 2026 —

## Operating Economics & Margin Trend

What the numbers say: Advanced Enzyme Technologies Ltd leads both opm at 31% and margin change at +4 percentage points.

Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Advanced Enzyme Technologies Ltd · 31% | 158.3% versus #2 · Rossari Biotech Ltd | 3/8 recent comparable periods | 3/3 companies · 58 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): 31%
2. Rossari Biotech Ltd (ROSSARI): 12%
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 9.8%

### Margin change — fastest expanders
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): +4.0 pp
2. Rossari Biotech Ltd (ROSSARI): 0.0 pp
3. Bombay Super Hybrid Seeds Ltd (BSHSL): −3.5 pp

### 20-quarter OPM history
- ADVENZYMES: Sep 2021 39% | Dec 2021 37% | Mar 2022 31% | Jun 2022 26% | Sep 2022 29% | Dec 2022 29% | Mar 2023 32% | Jun 2023 30% | Sep 2023 32% | Dec 2023 33% | Mar 2024 35% | Jun 2024 33% | Sep 2024 29% | Dec 2024 33% | Mar 2025 27% | Jun 2025 30% | Sep 2025 33% | Dec 2025 29% | Mar 2026 31% | Jun 2026 —
- ROSSARI: Sep 2021 12% | Dec 2021 11% | Mar 2022 12% | Jun 2022 13% | Sep 2022 13% | Dec 2022 14% | Mar 2023 13% | Jun 2023 14% | Sep 2023 13% | Dec 2023 14% | Mar 2024 13% | Jun 2024 13% | Sep 2024 13% | Dec 2024 13% | Mar 2025 12% | Jun 2025 12% | Sep 2025 12% | Dec 2025 12% | Mar 2026 11% | Jun 2026 12%
- BSHSL: Sep 2021 6.3% | Dec 2021 5.3% | Mar 2022 8.8% | Jun 2022 8.7% | Sep 2022 6.5% | Dec 2022 12% | Mar 2023 9.3% | Jun 2023 11% | Sep 2023 8.7% | Dec 2023 12% | Mar 2024 12% | Jun 2024 8.7% | Sep 2024 11% | Dec 2024 7.8% | Mar 2025 13% | Jun 2025 10% | Sep 2025 15% | Dec 2025 9.8% | Mar 2026 9.8% | Jun 2026 —

### 20-quarter Margin change history
- ADVENZYMES: Sep 2021 −9.8 pp | Dec 2021 −11.5 pp | Mar 2022 −10.7 pp | Jun 2022 −20.3 pp | Sep 2022 −10.2 pp | Dec 2022 −7.7 pp | Mar 2023 +1.4 pp | Jun 2023 +4.5 pp | Sep 2023 +3.4 pp | Dec 2023 +4.0 pp | Mar 2024 +3.0 pp | Jun 2024 +3.0 pp | Sep 2024 −3.0 pp | Dec 2024 0.0 pp | Mar 2025 −8.0 pp | Jun 2025 −3.0 pp | Sep 2025 +4.0 pp | Dec 2025 −4.0 pp | Mar 2026 +4.0 pp | Jun 2026 —
- ROSSARI: Sep 2021 −5.7 pp | Dec 2021 −5.1 pp | Mar 2022 −4.6 pp | Jun 2022 −2.8 pp | Sep 2022 +1.5 pp | Dec 2022 +2.9 pp | Mar 2023 +1.1 pp | Jun 2023 +0.7 pp | Sep 2023 −0.3 pp | Dec 2023 0.0 pp | Mar 2024 0.0 pp | Jun 2024 −1.0 pp | Sep 2024 0.0 pp | Dec 2024 −1.0 pp | Mar 2025 −1.0 pp | Jun 2025 −1.0 pp | Sep 2025 −1.0 pp | Dec 2025 −1.0 pp | Mar 2026 −1.0 pp | Jun 2026 0.0 pp
- BSHSL: Sep 2021 +2.1 pp | Dec 2021 +0.5 pp | Mar 2022 −1.5 pp | Jun 2022 +0.7 pp | Sep 2022 +0.2 pp | Dec 2022 +6.2 pp | Mar 2023 +0.6 pp | Jun 2023 +2.3 pp | Sep 2023 +2.1 pp | Dec 2023 +0.5 pp | Mar 2024 +2.3 pp | Jun 2024 −2.3 pp | Sep 2024 +2.3 pp | Dec 2024 −4.3 pp | Mar 2025 +1.7 pp | Jun 2025 +1.4 pp | Sep 2025 +4.5 pp | Dec 2025 +2.0 pp | Mar 2026 −3.5 pp | Jun 2026 —

## Profit Scale & Acceleration

What the numbers say: Advanced Enzyme Technologies Ltd leads with ₹173 crore of TTM profit, 14.6% above Rossari Biotech Ltd. Advanced Enzyme Technologies Ltd shows 29.1% growth from a ₹173 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Advanced Enzyme Technologies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Advanced Enzyme Technologies Ltd · ₹173 crore | 14.6% versus #2 · Rossari Biotech Ltd | 5/8 recent comparable periods | 3/3 companies · 48 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): ₹173 Cr
2. Rossari Biotech Ltd (ROSSARI): ₹151 Cr
3. Bombay Super Hybrid Seeds Ltd (BSHSL): ₹27 Cr

### Profit growth — fastest growers
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): 29%
2. Rossari Biotech Ltd (ROSSARI): 12%
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 1.0%

### 20-quarter Net profit history
- ADVENZYMES: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹28 Cr | Mar 2023 ₹32 Cr | Jun 2023 ₹29 Cr | Sep 2023 ₹35 Cr | Dec 2023 ₹42 Cr | Mar 2024 ₹30 Cr | Jun 2024 ₹35 Cr | Sep 2024 ₹33 Cr | Dec 2024 ₹39 Cr | Mar 2025 ₹27 Cr | Jun 2025 ₹40 Cr | Sep 2025 ₹45 Cr | Dec 2025 ₹43 Cr | Mar 2026 ₹45 Cr | Jun 2026 —
- ROSSARI: Sep 2021 ₹26 Cr | Dec 2021 ₹23 Cr | Mar 2022 ₹24 Cr | Jun 2022 ₹29 Cr | Sep 2022 ₹24 Cr | Dec 2022 ₹26 Cr | Mar 2023 ₹29 Cr | Jun 2023 ₹29 Cr | Sep 2023 ₹33 Cr | Dec 2023 ₹34 Cr | Mar 2024 ₹34 Cr | Jun 2024 ₹35 Cr | Sep 2024 ₹35 Cr | Dec 2024 ₹32 Cr | Mar 2025 ₹34 Cr | Jun 2025 ₹34 Cr | Sep 2025 ₹37 Cr | Dec 2025 ₹33 Cr | Mar 2026 ₹46 Cr | Jun 2026 ₹35 Cr
- BSHSL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹7 Cr | Mar 2023 ₹2 Cr | Jun 2023 ₹11 Cr | Sep 2023 ₹2 Cr | Dec 2023 ₹7 Cr | Mar 2024 ₹3 Cr | Jun 2024 ₹11 Cr | Sep 2024 ₹2 Cr | Dec 2024 ₹9 Cr | Mar 2025 ₹4 Cr | Jun 2025 ₹12 Cr | Sep 2025 ₹2 Cr | Dec 2025 ₹8 Cr | Mar 2026 ₹4 Cr | Jun 2026 —

### 20-quarter Profit growth history
- ADVENZYMES: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 50% | Mar 2024 -6.3% | Jun 2024 21% | Sep 2024 -5.7% | Dec 2024 -7.1% | Mar 2025 -10% | Jun 2025 14% | Sep 2025 36% | Dec 2025 10% | Mar 2026 67% | Jun 2026 —
- ROSSARI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 -7.7% | Dec 2022 13% | Mar 2023 21% | Jun 2023 0.0% | Sep 2023 38% | Dec 2023 31% | Mar 2024 17% | Jun 2024 21% | Sep 2024 6.1% | Dec 2024 -5.9% | Mar 2025 0.0% | Jun 2025 -2.9% | Sep 2025 5.7% | Dec 2025 3.1% | Mar 2026 35% | Jun 2026 2.9%
- BSHSL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 3.5% | Mar 2024 64% | Jun 2024 4.5% | Sep 2024 32% | Dec 2024 31% | Mar 2025 35% | Jun 2025 10% | Sep 2025 8.2% | Dec 2025 -14% | Mar 2026 4.5% | Jun 2026 —

## Capacity Spending & Returns On It

What the numbers say: There is not enough comparable evidence to name a reliable capex leader.

Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.

This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.

Evidence: No comparable leader | Not enough peers | Not enough history | 0/3 companies · 0 observations

Definition: CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.

### CAPEX — largest spenders

### CAPEX intensity — highest reinvestment intensity

### 20-quarter CAPEX history

### 20-quarter CAPEX intensity history

## Debt Load & Balance-Sheet Headroom

What the numbers say: Bombay Super Hybrid Seeds Ltd has the clearest covered balance-sheet capacity with ₹107 crore and gross debt of ₹108 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.

Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.

This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.

Evidence: Advanced Enzyme Technologies Ltd · ₹32 crore | 70.4% versus #2 · Bombay Super Hybrid Seeds Ltd | Not enough history | 3/3 companies · 45 observations

Definition: Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.

### Gross debt — lowest gross debt
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): ₹32 Cr
2. Bombay Super Hybrid Seeds Ltd (BSHSL): ₹108 Cr
3. Rossari Biotech Ltd (ROSSARI): ₹436 Cr

### Net debt — lowest net debt
1. Bombay Super Hybrid Seeds Ltd (BSHSL): ₹107 Cr
2. Rossari Biotech Ltd (ROSSARI): ₹321 Cr

### 20-quarter Gross debt history
- ADVENZYMES: Sep 2021 — | Dec 2021 — | Mar 2022 ₹35 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 ₹34 Cr | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹47 Cr | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 ₹39 Cr | Jun 2025 — | Sep 2025 ₹35 Cr | Dec 2025 — | Mar 2026 ₹32 Cr | Jun 2026 —
- ROSSARI: Sep 2021 ₹4 Cr | Dec 2021 ₹4 Cr | Mar 2022 ₹8 Cr | Jun 2022 ₹8 Cr | Sep 2022 ₹71 Cr | Dec 2022 ₹71 Cr | Mar 2023 ₹74 Cr | Jun 2023 ₹74 Cr | Sep 2023 ₹132 Cr | Dec 2023 ₹132 Cr | Mar 2024 ₹119 Cr | Jun 2024 ₹119 Cr | Sep 2024 ₹161 Cr | Dec 2024 ₹161 Cr | Mar 2025 ₹218 Cr | Jun 2025 ₹218 Cr | Sep 2025 ₹353 Cr | Dec 2025 ₹353 Cr | Mar 2026 ₹436 Cr | Jun 2026 ₹436 Cr
- BSHSL: Sep 2021 ₹2 Cr | Dec 2021 ₹2 Cr | Mar 2022 ₹39 Cr | Jun 2022 ₹39 Cr | Sep 2022 ₹0 Cr | Dec 2022 ₹0 Cr | Mar 2023 ₹53 Cr | Jun 2023 ₹53 Cr | Sep 2023 ₹22 Cr | Dec 2023 ₹22 Cr | Mar 2024 ₹48 Cr | Jun 2024 ₹48 Cr | Sep 2024 ₹37 Cr | Dec 2024 ₹37 Cr | Mar 2025 ₹92 Cr | Jun 2025 ₹92 Cr | Sep 2025 ₹30 Cr | Dec 2025 ₹30 Cr | Mar 2026 ₹108 Cr | Jun 2026 —

### 20-quarter Net debt history
- ROSSARI: Sep 2021 ₹-38 Cr | Dec 2021 ₹-38 Cr | Mar 2022 ₹-56 Cr | Jun 2022 ₹-56 Cr | Sep 2022 ₹-3 Cr | Dec 2022 ₹-3 Cr | Mar 2023 ₹-76 Cr | Jun 2023 ₹-77 Cr | Sep 2023 ₹53 Cr | Dec 2023 ₹53 Cr | Mar 2024 ₹48 Cr | Jun 2024 ₹51 Cr | Sep 2024 ₹81 Cr | Dec 2024 ₹81 Cr | Mar 2025 ₹112 Cr | Jun 2025 ₹101 Cr | Sep 2025 ₹276 Cr | Dec 2025 ₹276 Cr | Mar 2026 ₹321 Cr | Jun 2026 ₹321 Cr
- BSHSL: Sep 2021 ₹1 Cr | Dec 2021 ₹1 Cr | Mar 2022 ₹39 Cr | Jun 2022 ₹39 Cr | Sep 2022 ₹0 Cr | Dec 2022 ₹0 Cr | Mar 2023 ₹53 Cr | Jun 2023 ₹53 Cr | Sep 2023 ₹22 Cr | Dec 2023 ₹22 Cr | Mar 2024 ₹48 Cr | Jun 2024 ₹48 Cr | Sep 2024 ₹37 Cr | Dec 2024 ₹37 Cr | Mar 2025 ₹91 Cr | Jun 2025 ₹91 Cr | Sep 2025 ₹28 Cr | Dec 2025 ₹28 Cr | Mar 2026 ₹107 Cr | Jun 2026 —

## Return On Capital Employed

What the numbers say: Bombay Super Hybrid Seeds Ltd leads ROCE at 16%, 2 percentage points above Advanced Enzyme Technologies Ltd. Advanced Enzyme Technologies Ltd has the strongest latest improvement at +1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: Bombay Super Hybrid Seeds Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: Bombay Super Hybrid Seeds Ltd · 16% | 14.3% versus #2 · Advanced Enzyme Technologies Ltd | 0/8 recent comparable periods | 3/3 companies · 31 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. Bombay Super Hybrid Seeds Ltd (BSHSL): 16%
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): 14%
3. Rossari Biotech Ltd (ROSSARI): 13%

### ROCE change — fastest improvers
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): +1.0 pp
2. Rossari Biotech Ltd (ROSSARI): +0.3 pp
3. Bombay Super Hybrid Seeds Ltd (BSHSL): −5.0 pp

### 20-quarter ROCE history
- ROSSARI: Sep 2021 13% | Dec 2021 — | Mar 2022 13% | Jun 2022 — | Sep 2022 15% | Dec 2022 — | Mar 2023 15% | Jun 2023 — | Sep 2023 15% | Dec 2023 18% | Mar 2024 16% | Jun 2024 19% | Sep 2024 15% | Dec 2024 17% | Mar 2025 14% | Jun 2025 16% | Sep 2025 13% | Dec 2025 16% | Mar 2026 13% | Jun 2026 17%
- BSHSL: Sep 2021 29% | Dec 2021 — | Mar 2022 31% | Jun 2022 — | Sep 2022 31% | Dec 2022 — | Mar 2023 36% | Jun 2023 — | Sep 2023 36% | Dec 2023 46% | Mar 2024 35% | Jun 2024 43% | Sep 2024 31% | Dec 2024 39% | Mar 2025 30% | Jun 2025 39% | Sep 2025 28% | Dec 2025 32% | Mar 2026 25% | Jun 2026 —

### 20-quarter ROCE change history
- ROSSARI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 +2.1 pp | Dec 2022 — | Mar 2023 +1.5 pp | Jun 2023 — | Sep 2023 −0.1 pp | Dec 2023 — | Mar 2024 +1.0 pp | Jun 2024 — | Sep 2024 +0.1 pp | Dec 2024 −1.3 pp | Mar 2025 −2.1 pp | Jun 2025 −2.3 pp | Sep 2025 −2.0 pp | Dec 2025 −1.3 pp | Mar 2026 −1.1 pp | Jun 2026 +0.3 pp
- BSHSL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 +1.3 pp | Dec 2022 — | Mar 2023 +5.3 pp | Jun 2023 — | Sep 2023 +5.7 pp | Dec 2023 — | Mar 2024 −1.2 pp | Jun 2024 — | Sep 2024 −5.9 pp | Dec 2024 −6.9 pp | Mar 2025 −4.2 pp | Jun 2025 −3.7 pp | Sep 2025 −2.2 pp | Dec 2025 −6.4 pp | Mar 2026 −5.0 pp | Jun 2026 —

## Valuation Against Growth & Quality

What the numbers say: Rossari Biotech Ltd has the lowest comparable Guarded PEG at 1.7×. Only 1 of 3 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Rossari Biotech Ltd · 1.7× | Not enough peers | 0/8 recent comparable periods | 1/3 companies · 13 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.

### Guarded PEG — lowest PEG
1. Rossari Biotech Ltd (ROSSARI): 1.7

### P/E — lowest P/E
1. Rossari Biotech Ltd (ROSSARI): 18.0
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): 22.9
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 34.2

### 20-quarter Guarded PEG history
- ROSSARI: Sep 2021 4.9 | Dec 2021 2.5 | Mar 2022 2.1 | Jun 2022 3.2 | Sep 2022 5.7 | Dec 2022 — | Mar 2023 6.4 | Jun 2023 4.8 | Sep 2023 7.3 | Dec 2023 2.2 | Mar 2024 1.7 | Jun 2024 1.6 | Sep 2024 1.4 | Dec 2024 1.7 | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —

### 20-quarter P/E history
- ADVENZYMES: Sep 2021 28.4 | Dec 2021 25.6 | Mar 2022 25.9 | Jun 2022 25.1 | Sep 2022 30.3 | Dec 2022 32.7 | Mar 2023 26.5 | Jun 2023 28.8 | Sep 2023 30.0 | Dec 2023 32.9 | Mar 2024 27.8 | Jun 2024 29.9 | Sep 2024 38.0 | Dec 2024 26.7 | Mar 2025 21.9 | Jun 2025 28.1 | Sep 2025 26.1 | Dec 2025 22.5 | Mar 2026 20.7 | Jun 2026 —
- ROSSARI: Sep 2021 86.9 | Dec 2021 72.5 | Mar 2022 52.6 | Jun 2022 48.5 | Sep 2022 52.5 | Dec 2022 40.3 | Mar 2023 32.1 | Jun 2023 44.8 | Sep 2023 41.7 | Dec 2023 37.8 | Mar 2024 29.8 | Jun 2024 35.6 | Sep 2024 37.1 | Dec 2024 31.7 | Mar 2025 24.6 | Jun 2025 27.7 | Sep 2025 25.8 | Dec 2025 23.3 | Mar 2026 16.0 | Jun 2026 19.9
- BSHSL: Sep 2021 31.2 | Dec 2021 34.1 | Mar 2022 38.3 | Jun 2022 40.1 | Sep 2022 99.0 | Dec 2022 194.4 | Mar 2023 237.2 | Jun 2023 173.7 | Sep 2023 128.9 | Dec 2023 135.2 | Mar 2024 111.2 | Jun 2024 90.5 | Sep 2024 82.9 | Dec 2024 65.9 | Mar 2025 50.1 | Jun 2025 57.0 | Sep 2025 50.0 | Dec 2025 41.9 | Mar 2026 26.7 | Jun 2026 —

## Enterprise Value & Book Value

What the numbers say: Rossari Biotech Ltd leads both ev/ebitda at 10.1× and p/bv at 2.03×.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.

Evidence: Rossari Biotech Ltd · 10.1× | 14.4% versus #2 · Advanced Enzyme Technologies Ltd | 0/8 recent comparable periods | 3/3 companies · 58 observations

Definition: EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.

### EV/EBITDA — lowest EV/EBITDA
1. Rossari Biotech Ltd (ROSSARI): 10.1
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): 11.8
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 20.1

### P/BV — lowest P/BV
1. Rossari Biotech Ltd (ROSSARI): 2.0
2. Advanced Enzyme Technologies Ltd (ADVENZYMES): 2.2
3. Bombay Super Hybrid Seeds Ltd (BSHSL): 7.0

### 20-quarter EV/EBITDA history
- ADVENZYMES: Sep 2021 16.5 | Dec 2021 14.4 | Mar 2022 13.9 | Jun 2022 13.6 | Sep 2022 16.2 | Dec 2022 17.6 | Mar 2023 13.8 | Jun 2023 15.9 | Sep 2023 17.5 | Dec 2023 19.2 | Mar 2024 16.4 | Jun 2024 17.3 | Sep 2024 22.3 | Dec 2024 15.8 | Mar 2025 12.9 | Jun 2025 15.9 | Sep 2025 15.0 | Dec 2025 12.9 | Mar 2026 11.8 | Jun 2026 —
- ROSSARI: Sep 2021 54.5 | Dec 2021 43.7 | Mar 2022 28.4 | Jun 2022 23.8 | Sep 2022 24.8 | Dec 2022 17.9 | Mar 2023 14.3 | Jun 2023 20.7 | Sep 2023 19.3 | Dec 2023 18.9 | Mar 2024 15.3 | Jun 2024 17.9 | Sep 2024 19.6 | Dec 2024 17.2 | Mar 2025 13.2 | Jun 2025 14.6 | Sep 2025 13.3 | Dec 2025 12.4 | Mar 2026 8.8 | Jun 2026 10.1
- BSHSL: Sep 2021 24.6 | Dec 2021 24.4 | Mar 2022 28.5 | Jun 2022 31.3 | Sep 2022 73.2 | Dec 2022 145.7 | Mar 2023 185.5 | Jun 2023 133.0 | Sep 2023 100.3 | Dec 2023 102.2 | Mar 2024 81.5 | Jun 2024 70.1 | Sep 2024 63.2 | Dec 2024 49.5 | Mar 2025 39.6 | Jun 2025 43.8 | Sep 2025 39.6 | Dec 2025 32.0 | Mar 2026 20.1 | Jun 2026 —

### 20-quarter P/BV history
- ADVENZYMES: Sep 2021 4.4 | Dec 2021 3.6 | Mar 2022 3.2 | Jun 2022 3.1 | Sep 2022 2.6 | Dec 2022 2.7 | Mar 2023 2.4 | Jun 2023 2.9 | Sep 2023 2.9 | Dec 2023 3.4 | Mar 2024 3.1 | Jun 2024 3.5 | Sep 2024 4.2 | Dec 2024 2.9 | Mar 2025 2.3 | Jun 2025 2.8 | Sep 2025 2.5 | Dec 2025 2.2 | Mar 2026 2.0 | Jun 2026 —
- ROSSARI: Sep 2021 18.7 | Dec 2021 9.3 | Mar 2022 6.8 | Jun 2022 5.8 | Sep 2022 6.2 | Dec 2022 4.7 | Mar 2023 4.1 | Jun 2023 5.2 | Sep 2023 4.9 | Dec 2023 4.5 | Mar 2024 3.8 | Jun 2024 5.1 | Sep 2024 4.8 | Dec 2024 3.9 | Mar 2025 3.0 | Jun 2025 3.2 | Sep 2025 2.9 | Dec 2025 2.5 | Mar 2026 1.8 | Jun 2026 2.5
- BSHSL: Sep 2021 10.5 | Dec 2021 9.5 | Mar 2022 11.9 | Jun 2022 14.5 | Sep 2022 25.0 | Dec 2022 50.0 | Mar 2023 97.8 | Jun 2023 73.9 | Sep 2023 65.5 | Dec 2023 41.0 | Mar 2024 34.1 | Jun 2024 35.7 | Sep 2024 24.0 | Dec 2024 16.7 | Mar 2025 13.9 | Jun 2025 19.2 | Sep 2025 13.2 | Dec 2025 9.7 | Mar 2026 5.9 | Jun 2026 —

## Market action

Advanced Enzyme Technologies Ltd has the strongest one-year price move in Seeds/Tissue Culture/Bio Technology at -2.2%. It also leads on Mansfield relative strength against NIFTY at +0.8%. 1 of 3 covered companies is above zero on that measure. Every line covers 313 weekly closes through 2026-07-24.

### Strongest one-year price performers
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): -2.2%
2. Rossari Biotech Ltd (ROSSARI): -34%
3. Bombay Super Hybrid Seeds Ltd (BSHSL): -37%

### Strongest relative strength versus NIFTY 500
1. Advanced Enzyme Technologies Ltd (ADVENZYMES): 0.8%
2. Rossari Biotech Ltd (ROSSARI): -12%
3. Bombay Super Hybrid Seeds Ltd (BSHSL): -17%

## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Capital expenditure, Valuation have fewer than three usable current readings.

## Every company
- Advanced Enzyme Technologies Ltd (ADVENZYMES) — market value ₹3.6K Cr; latest fundamentals Mar 2026; second-feed figures WITHHELD
- Rossari Biotech Ltd (ROSSARI) — market value ₹2.7K Cr; latest fundamentals Jun 2026
- Bombay Super Hybrid Seeds Ltd (BSHSL) — market value ₹913 Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures

## Source standing of each company

Cross-checked: 1. Unverified: 1. Withheld: 1. Graded companies: 3.

1 of 3 companies draws at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear.

1 of 3 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Advanced Enzyme Technologies Ltd (ADVENZYMES) — its two data sources disagree by up to 4% on reported income across 14 comparable periods, so its derived ratios are withheld.

- WITHHELD | ADVENZYMES | Advanced Enzyme Technologies Ltd | diff_gt_2pct | disagreement up to 3.96% over 14 comparable periods

- UNVERIFIED | BSHSL | Bombay Super Hybrid Seeds Ltd | too little overlapping reported history to cross-check the second feed

## Methodology and freshness

Fundamentals through Jun 2026; prices through 2026-07-24.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### What is the Nifty Seeds/Tissue Culture/Bio Technology index?

The Nifty Seeds/Tissue Culture/Bio Technology index tracks India's listed Seeds/Tissue Culture/Bio Technology companies as a single basket. This page follows the same 3 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Seeds/Tissue Culture/Bio Technology sector rather than to its largest constituent. Figures are as of Jun 2026.

### Which are the best Seeds/Tissue Culture/Bio Technology stocks in India?

Ranked by this page's four-factor score, Advanced Enzyme Technologies Ltd places first among 3 listed Seeds/Tissue Culture/Bio Technology companies, followed by Rossari Biotech Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Seeds/Tissue Culture/Bio Technology stocks are listed in India?

This comparison covers 3 listed Seeds/Tissue Culture/Bio Technology companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

### Which Seeds/Tissue Culture/Bio Technology company is the biggest?

Rossari Biotech Ltd is the largest, with trailing-twelve-month revenue of ₹2,550 crore, ahead of Advanced Enzyme Technologies Ltd at ₹746 crore. That covers 3 of 3 companies with comparable reporting through Jun 2026.

### Which Seeds/Tissue Culture/Bio Technology company is growing fastest?

Rossari Biotech Ltd has the fastest revenue growth at 19.4% year on year, across 3 of 3 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.

### Which Seeds/Tissue Culture/Bio Technology company has the best profit margins?

Advanced Enzyme Technologies Ltd has the highest operating margin at 31%, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Seeds/Tissue Culture/Bio Technology company makes the most profit?

Advanced Enzyme Technologies Ltd earns the most, at ₹173 crore of trailing-twelve-month net profit, from 3 of 3 comparable companies. Advanced Enzyme Technologies Ltd has the fastest profit growth at 29.1%, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Seeds/Tissue Culture/Bio Technology company earns the highest return on capital?

Bombay Super Hybrid Seeds Ltd leads on return on capital employed at 16%, across 3 of 3 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Seeds/Tissue Culture/Bio Technology stock is the cheapest?

On guarded PEG — where a LOWER number is cheaper — Rossari Biotech Ltd screens cheapest at 1.7×. Only 1 of 3 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Which Seeds/Tissue Culture/Bio Technology company has the strongest balance sheet?

Advanced Enzyme Technologies Ltd carries the lowest comparable gross debt at ₹32 crore, from 3 of 3 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.

### Is the Seeds/Tissue Culture/Bio Technology sector beating the market?

Seeds/Tissue Culture/Bio Technology has underperformed NIFTY 500 by 27.1% over the last 52 weeks and 4.8% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 3 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Seeds/Tissue Culture/Bio Technology stock has the strongest price momentum?

Advanced Enzyme Technologies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Seeds/Tissue Culture/Bio Technology company scores highest for research priority?

Advanced Enzyme Technologies Ltd scores 73.1 out of 100 with 76% evidence confidence, from 27.8 points on growth and earnings, 17.5 on capital efficiency, 12.1 on valuation and 15.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Seeds/Tissue Culture/Bio Technology companies does this comparison cover, and over what period?

It compares 3 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Seeds/Tissue Culture/Bio Technology sector?

The 3 Seeds/Tissue Culture/Bio Technology companies on this page carry ₹7,180 crore of combined market value. Advanced Enzyme Technologies Ltd is the largest at ₹3,554 crore, about 49% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.

### How is the Seeds/Tissue Culture/Bio Technology sector performing?

1 of the 3 covered Seeds/Tissue Culture/Bio Technology companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 27.1% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-07-29.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Narrative sector analysis: https://www.sectoralpha.in/sectors/seeds-tissue-culture-bio-technology